ASCO GU 2018: An Observational Study Profiling Biospecimens from 10,000 Metastatic Prostate Cancer Patients to Screen for Molecular Alterations
Methods:
Using a virtual clinical trial model to maximize patient access and enrollment, this study is NGS to 10,000 men with metastatic PC (Mpc). Patients with histologically-documented mPC and surplus formalin-fixed paraffin-embedded tumor tissue are eligible for enrollment. Leftover archival tissue is submitted for NGS to Strata Oncology, a clinical laboratory improvement amendments (CLIA)-certified lab. The Strata NGS assay sequences DNA and RNA, and simultaneously detects a range of actionable genomic alterations including gene mutations, small insertions and deletions, copy number changes, and gene fusions in 87 cancer-related genes. Microsatellite instability status is determined via the number of length variant alleles observed in NGS sequencing data at several microsatellite loci. Test reports that will be presented to the clinician, will include all positive and negative variants detected, and information regarding potential matching therapeutic protocols. Clinical trial information: NCT03061305
Presented by: Won Kim, MD University of California, San Francisco, USA
Co Authors: Kat Kwiatkowski, Justin Brown, Dan R Rhodes, Scott A Tomlins, Felix Y Feng, Eric Jay Small; University of California San Francisco, San Francisco, CA; Strata Oncology, Ann Arbor, MI
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA